ACLY and neoplasm: To explore mechanisms underlying reduced tumour burden in Acly-KO mice, we performed bulk RNA-seq on liver tumours from WT (n = 9) and Acly-KO (n = 12) mice at two timepoints following AAV injection: a late timepoint (8 weeks; Fig. 1a–h and Extended Data Fig. 2) and an early timepoint (4 weeks), before detectable differences in tumour burden (Extended Data Fig. 7a,b).